Table 3.
Immunologic response to antiretroviral therapy among HIV-1-infected children
Increase in CD4% from baseline following initiation of ART in all children (n = 65) | ||||
---|---|---|---|---|
Duration of follow-up (months) |
Number of childrena |
Median CD4% (IQR) |
Median CD4% increase from baseline (IQR) |
Pb |
6 |
42 |
23.3% (18.0 – 28.5) |
11% (4 – 15) |
< 0.001 |
12 |
37 |
27% (20 – 34) |
15% (7 – 20) |
< 0.001 |
18 |
30 |
27.5% (16 – 36) |
17% (6 – 22) |
< 0.001 |
24 |
25 |
29% (21 – 38) |
18.5% (5 – 22) |
0.0001 |
30 |
19 |
32% (19 – 38) |
15% (9 – 24) |
0.0001 |
36 | 12 | 30.3% (22.5 – 39.5) | 18.5% (10.8 – 24.5) | 0.002 |
a Number of children tested at corresponding length of follow-up. Attrition in numbers is attributable to lack of data, loss to follow-up or death.
b Wilcoxon signed ranks test.